Share on StockTwits

Isis Pharmaceuticals (NASDAQ:ISIS) SVP Richard S. Geary sold 22,200 shares of Isis Pharmaceuticals stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $50.05, for a total value of $1,111,110.00. Following the completion of the sale, the senior vice president now directly owns 4,955 shares of the company’s stock, valued at approximately $247,998. The transaction was disclosed in a filing with the SEC, which is available at this link.

ISIS has been the subject of a number of recent research reports. Analysts at Deutsche Bank initiated coverage on shares of Isis Pharmaceuticals in a research note to investors on Wednesday. They set a “buy” rating and a $60.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note to investors on Tuesday. They now have a $49.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note to investors on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $39.50.

Isis Pharmaceuticals (NASDAQ:ISIS) traded down 3.49% on Friday, hitting $48.42. The stock had a trading volume of 1,145,267 shares. Isis Pharmaceuticals has a 52 week low of $12.95 and a 52 week high of $51.72. The stock’s 50-day moving average is $42.24 and its 200-day moving average is $34.35. The company’s market cap is $5.620 billion.

Isis Pharmaceuticals (NASDAQ:ISIS) last released its earnings data on Tuesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.06. The company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $19.82 million. During the same quarter last year, the company posted ($0.37) earnings per share. Isis Pharmaceuticals’s revenue was up 103.4% compared to the same quarter last year. On average, analysts predict that Isis Pharmaceuticals will post $-0.52 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.